Shattuck Labs, Inc. (STTK) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Shattuck Labs, Inc. in 2026. The next earnings report is expected on November 10, 2026.
Next earnings date
10 Nov 2026
In 82 days
EPS estimate
-0.12
Revenue estimate
0
Past earnings
Latest earnings analysis
Shattuck Labs beat consensus on EPS, with EPS of a $0.12 loss versus an estimated $0.1241 loss, and revenue met expectations at $0. In the prior quarter, EPS also came in ahead of expectations while revenue met estimates.
No dividend history available.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc. (STTK) is scheduled to report earnings on November 10, 2026.
Shattuck Labs, Inc. (STTK) last reported earnings on August 11, 2026.
Shattuck Labs, Inc. (STTK) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.